Lipid metabolism as a target for brain cancer therapy: Synergistic activity of lovastatin and sodium phenylacetate against human glioma cells

Journal of Neurochemistry

Volumn 66, Issue 2, 1996, Pages 710-716

  Prasanna, Premakala ^a   Thibault, Alain ^a,b   Liu, Lei ^a,b   Samid, Dvorit ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Glioblastoma; Lovastatin; Mevalonate pathway; Nuclear receptor; Phenotypic reversion; Phenylacetic acid, sodium salt

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANTINEOPLASTON AS2-1; MEVINOLIN; PEROXISOME PROLIFERATOR; TRANSFORMING GROWTH FACTOR BETA2; UBIQUINONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME REGULATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID METABOLISM; PRIORITY JOURNAL;

EID: 0030027536     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1996.66020710.x     Document Type: Article

References (49)

1. Apfel R., Benbrook D., Lerahardt E., and Ortiz M. A. (1994) A novel receptor specific for a subset of thyroid hormone responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol. Cell. Biol. 14, 7025-7035.
2. Azarnoff D. L., Curran G. L., and Williamson W. P. (1958) Incorporation of acetate-1-C14 into cholesterol by human intracranial tumors in vitro. J. Natl. Cancer Inst. 21, 1109-1115.
3. Brandes A., Soesan M., and Fiorentino M. V. (1991) Medical treatment of high grade gliomas in adults: an overview. Anticancer Res. 11, 719-728.
4. Brusilow S. W., Danney M., Waher L. J., Batshaw M., Burton B., Levitsky K., Roth C., McKeethren C., and Ward J. (1984) Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N. Engl. J. Med. 310, 1630-1634.
5. Casey P. J., Solski P. A., Der C. J., and Buss J. E. (1989) P21 ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. USA 86, 8323-8327.
6. Castillo M., Zafra M. F., and Garcia-Peregrin E. (1988) Inhibition of brain and liver 3-OH-3-methylglutaryl-CoA reductase and mevalonate-5-pyrophosphate decarboxylase in experimental phenylalaninemia. Neurochem. Res. 13, 551-555.
7. Castillo M., Martinez-Cayuela M., Zafra M. F., and Garcia-Peregrin E. (1991) Effect of phenylalanine derivatives on the main regulatory enzymes of cholesterogenesis. Mol. Cell. Biochem. 105, 21-25.
8. Declue J. E., Vass W. C., Papageorge A. G., Lowy D. R., and Williamson B. M. (1991) Inhibition of cell growth by lovastatin is independent of ras function. Cancer Res. 51, 712-717.
9. Depierre J. W. and Ernster L. (1977) Enzyme topology of intracellular membranes. Annu. Rev. Biochem. 46, 201-262.
10. Fairbanks K. P., Witte L. D., and Goodman D. S. (1984) Relationship between mevalonate and mitogenesis in human fibroblasts stimulated with platelet-derived growth factor. J. Biol. Chem. 259, 1546-1551.
11. Fontana A., Hengartner H., Tribolet N., and Weber E. (1984) Gli-oblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J. Immunol. 132, 1837-1844.
12. Fumagalli R., Grossi E., Paoletti P., and Paoletti R. (1964) Studies on lipids in brain tumors. Occurrence and significance of sterol precursors of cholesterol in human brain tumors. J Neurochem. 11, 561-565.
13. Goldstein J. L., Helgeson J. A. S., and Brown M. S. (1979) Inhibition of cholesterol synthesis with compactin renders growth of cultured cells dependent on the low density lipoprotein receptor. J. Biol. Chem. 254, 5403-5409.
14. Goltlicher M., Widmark E , Li Q., and Gustafsson J. A. (1992) Fatty acids activate a chimera of the clofibric-activated receptor and the glucocorticoid receptor. Proc. Natl. Acad Sci. USA. 89, 4653-4657.
15. Gulick T., Cresci S., Caira T., Moore D., and Kelly D. P. (1994) The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc. Natl. Acad. Sci. USA 91, 11012-11016
16. Habenicht A. J. R., Glomset J. A., and Ross R. (1980) Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and Swiss 3T3 cells stimulated to divide by platelet-derived growth factor. J. Biol. Chem. 255, 5134-5140
17. Hammerling G. J., Klar D., Pulm W., Momburg F., and Moldenhauer G. (1987) The influence of major histocompatibility complex class 1 antigens on tumor growth and metastasis. Biochim. Biophys. Acta 907, 245-259.
18. Hancock J. F., Magee A. I., Childs J. E., and Marshall C. J. (1989) All ras proteins are poly isoprenylated but some are palmitoy-lated. Cell 57, 1167-1177.
19. Illingworth D. R. and Bacon S. (1989) Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs. Arteriosclerosis 9, I121-I134.
20. Isemann I. and Green S. (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650.
21. Jackson J. H., Cochrane C. G., Bourne J. R., Solski P. A., Buss J. E., and Der C. J. (1990) Farnesol modification of kirsten-ras exon 4B protein is essential for transformation. Proc. Natl. Acad. Sci. USA. 87, 3042-3046.
22. Kehrl J. H., Roberts A. B., Wakefield L. M., Jakowlew S., Sporn M. B., and Fauci A. S. (1986) Transforming growth B is an important immunomodulatory protein for human B lymphocytes. J. Immunol. 137, 3855-3860.
23. Loo Y. H., Scotto J., and Wisniewski H. M. (1978) Myelin deficiency in experimental phenylketonuria: contribution of the aromatic acid metabolites of phenylalanine. Adv. Exp. Med. Biol. 100, 453-469.
24. Mahaly M., Urso M., Wahley R., Blue M., Williams T., Guaspari A., and Selker R. G. (1985) Immunobiology of primary intracranial tumors. J. Neurosurg. 63, 719-725.
25. Maltese W. A. (1984) Induction of differentiation in murine neuroblastoma cells by mevinolin, a competitive inhibitor of 3-hydroxy-3-rnetbylglutaryl coenzyme A reductase. Biochem. Biophys. Res. Commun. 120, 454-460.
26. Maltese W. A. and Sheridan K. M. (1985) Differentiation of neuroblastoma cells induced by an inhibitor of mevalonate synthesis: relation of neunte outgrowth and acetylcholinesrerase activity to changes in cell proliferation and blocked isoprenoid synthesis. J. Cell. Physiol. 125, 540-558.
27. Maltese W. A. and Sheridan K. M. (1987) Isoprenylated proteins in cultured cells: subcellular distribution and changes related to altered morphology and growth arrest induced by mevatonate deprivation. J. Cell Physiol. 133, 471-481.
28. Maltese W. A., Defendini R., Green R. A., Sheridan K. M., and Donley D. K. (1985) Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Clin. Invest. 76, 1748-1754.
29. Maxwell M., Galanopoulos T., Neville-Golden J., and Antoniades H. N. (1992) Effect of the expression of transforming growth factor-beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J. Neurosurg. 76, 799-804.
30. Moynihan T. and Grossman S. (1994) The role of chemotherapy in the treatment of primary tumors of the central nervous system. Cancer Invest. 12, 88-97.
31. Paoletti P., Soloway A. H., Whitman B., and Messer J. R. (1966) Lipid biosynthesis from labelled precursors in an experimental brain-tumor bearing mouse. Neurochirurgia (Stuttg) 9, 12-18.
32. Quesney-Huneeus V., Wiley M. H., and Siperstein M D. (1979) Essential role for mevalonate synthesis in DNA replication. Proc. Natl. Acad. Sci. USA. 76, 5056-5060.
33. Quesney-Huneeus V., Galick H. A., Siperstein M. D., Erickson S. K., Spencer T. A., and Nelson J. A. (1983) The dual role of mevalonate in the cell cycle. J. Biol. Chem. 258, 378-385.
34. Ram Z., Samid D., Walbridge S., Oshiro E. M., Viola J. J., Ta-Cheng J.-H., Shack S., Thibault A., Myers C. E., and Oldfield E. H. (1994) Cancer Res. 54, 2923-2927.
35. Rine J. and Kim S H. (1990) A role for isoprenoid lipids in the localization and function of an oncoprotein. New Biol. 2, 219-226.
36. Roberts A. B., Sporn M. B., Assoian J. M., Smith N. S., Wakefield L. M., Heine V. I., Liotta L. A., Falanga V., Kehrl J. H., and Fauchi A. S. (1986) Transforming growth type beta, rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl. Acad. Sci. USA. 83, 4167-14171.
37. Rodriques J. C., Gil-Gomez G., Hegardt F. G., and Haro D. (1994) Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. J. Biol. Chem. 269, 18767-18772.
38. Samid D., Shack S., and Sherman L. T. (1992) Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res. 52, 1988-1992.
39. Samid D., Ram Z., Hudgins W. R., Shack S., Liu L., Walbridge S., Oldfield E. H., and Myers C. E. (1994) Selective activity of phenylacetate against malignant gliomas: resemblance to fetal damage in phenylketonuria. Cancer Res. 54, 891-895.
40. Sebti S. M., Tkalavic G. T., and Jani J. P. (1991) Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-Ras oncogene transformed cells in nude mice. Cancer Commun. 3, 141-147.
41. Sher T., Yi H. F., McBride O. W., and Gonzalez F. J. (1993) cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32, 5598-5604.
42. Simell O., Sipila I., Rajantie J., Valle D. L., and Brusilow S. W. (1986) Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance. Pediatr. Res. 20, 1117-1121.
43. Soma M. R., Pagliarini P., Butti G., Paoletti R., Paoletti P., and Fumagalli R. (1992) Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N′-bis(2-chloroethyl)-N-nitrosourea and B-interferon on human glioma cells. Cancer Res. 52, 4348-4355.
44. Thibault A., Cooper M. R., Figg W. D., Venzon D. J., Sartor A. O., Tompkins A. C., Weinberger M. S., Headlee D. J., McCall N. A., Samid D., and Myers C. E. (1994) A phase 1 and pharmacokinetic study of intravenous PA in patients with cancer. Cancer Res. 54, 1690-1694.
45. Thibault A., Samid D., Cooper M. R., Figg W. D., Tompkins A. C., Patronas N., Headlee D. J., Kohler D. R., Venzon D. J., and Myers C. E. (1995a) Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer 75, 2932-2938.
46. Thibault A., Samid D., Cooper M. R., Hohl R., Patronas N., Figg W. D., Venzon D., Tompkins A. C., McCall N. A., and Myers C. E. (1995b) Phase I studies with lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin. Cancer Res. (in press).
47. Vorburger K., Kitten G. T., and Nigg E. A. (1989) Modification of nuclear proteins by mevalonic acid occurs in reticulocyte lysates and requires the cysteine residues of the C-terminal CXXM motif. EMBO J. 8, 4007-4014.
48. Wen G. Y., Wisniewski H. M., Shek J. W., Loo Y. H., and Fulton T. R. (1980) Neuropathology of phenylacetate poisoning in rats: an experimental model of phenylketonuria. Ann. Neurol. 7, 557-566.
49. Wolda S. L. and Glomset J. A. (1988) Evidence for modification of lamin B by a product of mevalonic acid. J. Biol. Chem. 263, 5997-6000.